{"title":"On a Holm-related MTP for rejecting at least <i>k</i> hypotheses: general validity, optimality property, confidence regions, and applications.","authors":"Olivier J M Guilbaud","doi":"10.1080/10543406.2024.2429478","DOIUrl":null,"url":null,"abstract":"<p><p>This article concerns <i>p</i>-value-based multiple testing procedures (MTPs) that can be used in a confirmatory clinical study under minimal assumptions in case the requirement for study-success is that at least <i>k</i> out of <i>m</i> primary/important hypotheses become rejected. Recently, a simple, generally valid Holm-type MTP was discussed that can be used for such a requirement for any <i>k</i> from one to <i>m</i>. It can only reject at least <i>k</i> (or zero) hypotheses, but this increases the power to reject <i>k</i> or more hypotheses compared to Holm's step-down MTP. The present article provides a simple formulation and proof of strong family-wise error rate (FWER) control for a stepwise MTP that is sharper in that for any <i>k</i> strictly between one and <i>m</i> it: (a) always rejects at least as much, and (b) can potentially reject fewer than <i>k</i> hypotheses. This sharper MTP too is generally valid, without any assumption about logical or stochastic relationships. It has a gatekeeping step, followed by <i>m</i> steps where ordered primary <i>p</i>-values are compared to critical constants and rejections are made in a step-down manner. These constants have the optimality property that under a natural monotonicity restriction, they cannot be increased without losing the general strong FWER control. Confidence regions like those for Holm's MTP are provided. Applications are discussed in connection with three interesting approaches proposed earlier for confirmatory studies: (a) the Superiority-Noninferiority approach; (b) Fallback tests for co-primary endpoints; and (c) Multistage gatekeeping MTPs that utilize so-called <i>k</i>-truncated Holm MTPs in some stages.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-19"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2429478","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
This article concerns p-value-based multiple testing procedures (MTPs) that can be used in a confirmatory clinical study under minimal assumptions in case the requirement for study-success is that at least k out of m primary/important hypotheses become rejected. Recently, a simple, generally valid Holm-type MTP was discussed that can be used for such a requirement for any k from one to m. It can only reject at least k (or zero) hypotheses, but this increases the power to reject k or more hypotheses compared to Holm's step-down MTP. The present article provides a simple formulation and proof of strong family-wise error rate (FWER) control for a stepwise MTP that is sharper in that for any k strictly between one and m it: (a) always rejects at least as much, and (b) can potentially reject fewer than k hypotheses. This sharper MTP too is generally valid, without any assumption about logical or stochastic relationships. It has a gatekeeping step, followed by m steps where ordered primary p-values are compared to critical constants and rejections are made in a step-down manner. These constants have the optimality property that under a natural monotonicity restriction, they cannot be increased without losing the general strong FWER control. Confidence regions like those for Holm's MTP are provided. Applications are discussed in connection with three interesting approaches proposed earlier for confirmatory studies: (a) the Superiority-Noninferiority approach; (b) Fallback tests for co-primary endpoints; and (c) Multistage gatekeeping MTPs that utilize so-called k-truncated Holm MTPs in some stages.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.